Editorial: Proglucagon-Derived Peptides ‌ Peter R. Flatt, Filip K. Knop, Filip K. Knop, Filip K. Knop, Filip K. Knop, Andrei I. Tarasov

Ստացեք ամբողջական տեքստը

Amylin and Calcitonin: Potential Therapeutic Strategies to Reduce Body Weight and Liver Fat ‌ David S. Mathiesen, Asger Lund, Tina Vilsbøll, Tina Vilsbøll, Tina Vilsbøll, Filip K. Knop, Filip K. Knop, Filip K. Knop, Filip K. Knop, Jonatan I. Bagger, Jonatan I. Bagger

Ստացեք ամբողջական տեքստը

Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD ‌ Marta Seghieri, Marta Seghieri, Alexander S. Christensen, Andreas Andersen, Anna Solini, Filip K. Knop, Filip K. Knop, Filip K. Knop, Tina Vilsbøll, Tina Vilsbøll

Ստացեք ամբողջական տեքստը

A glucose-insulin-glucagon coupled model of the isoglycemic intravenous glucose infusion experiment ‌ Vijaya Subramanian, Jonatan I. Bagger, Jonatan I. Bagger, Jonatan I. Bagger, Jens J. Holst, Jens J. Holst, Filip K. Knop, Filip K. Knop, Filip K. Knop, Filip K. Knop, Tina Vilsbøll, Tina Vilsbøll, Tina Vilsbøll

Ստացեք ամբողջական տեքստը

Glucagon Receptor Signaling and Lipid Metabolism ‌ Katrine D. Galsgaard, Katrine D. Galsgaard, Jens Pedersen, Jens Pedersen, Filip K. Knop, Filip K. Knop, Filip K. Knop, Jens J. Holst, Jens J. Holst, Nicolai J. Wewer Albrechtsen, Nicolai J. Wewer Albrechtsen, Nicolai J. Wewer Albrechtsen

Ստացեք ամբողջական տեքստը

Hypoglycaemia and cardiac arrhythmias in diabetes ‌ Andreas Andersen, Peter G. Jørgensen, Filip K. Knop, Tina Vilsbøll

Ստացեք ամբողջական տեքստը

Bone Status in Obese, Non-diabetic, Antipsychotic-Treated Patients, and Effects of the Glucagon-Like Peptide-1 Receptor Agonist Exenatide on Bone Turnover Markers and Bone Mineral... ‌ Robert Eriksson, Robert Eriksson, Brian V. Broberg, Pelle L. Ishøy, Nikolaj Bak, Ulrik B. Andersen, Niklas R. Jørgensen, Niklas R. Jørgensen, Filip K. Knop, Filip K. Knop, Filip K. Knop, Bjørn H. Ebdrup, Bjørn H. Ebdrup, Bjørn H. Ebdrup

Ստացեք ամբողջական տեքստը

Accuracy of continuous glucose monitoring during exercise-related hypoglycemia in individuals with type 1 diabetes ‌ Kaisar Maytham, Kaisar Maytham, Per G. Hagelqvist, Per G. Hagelqvist, Susanne Engberg, Julie L. Forman, Ulrik Pedersen-Bjergaard, Ulrik Pedersen-Bjergaard, Filip K. Knop, Filip K. Knop, Filip K. Knop, Tina Vilsbøll, Tina Vilsbøll, Tina Vilsbøll, Andreas Andersen, Andreas Andersen

Ստացեք ամբողջական տեքստը

Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes – a review ‌ Katrine B Hansen, Tina Vilsbøll, Filip K Knop

Ստացեք ամբողջական տեքստը

Protocol for assessing the effects of exogenous hormone administration on human postprandial glucose metabolism, appetite sensations, and food intake ‌ Christoffer A. Hagemann, Lærke S. Gasbjerg, Mikkel B. Christensen, Filip K. Knop

Ստացեք ամբողջական տեքստը

Two weeks of acarbose treatment shows no effect on gut microbiome composition in patients with type 2 diabetes: a randomised, placebocontrolled, double-blind, crossover study ‌ Niels B Dalsgaard, Lærke S Gasbjerg, Laura S Hansen, Dennis S Nielsen, Torben S Rasmussen, Filip K Knop

Ստացեք ամբողջական տեքստը

Mechanisms of the incretin effect in subjects with normal glucose tolerance and patients with type 2 diabetes. ‌ Andrea Mari, Jonatan I Bagger, Ele Ferrannini, Jens J Holst, Filip K Knop, Tina Vilsbøll

Ստացեք ամբողջական տեքստը

Model‐Based Prediction of Plasma Concentration and Enterohepatic Circulation of Total Bile Acids in Humans ‌ Benjamin Guiastrennec, David P. Sonne, Martin Bergstrand, Tina Vilsbøll, Filip K. Knop, Mats O. Karlsson

Ստացեք ամբողջական տեքստը

No changes in levels of bone formation and resorption markers following a broad-spectrum antibiotic course ‌ Kristian H. Mikkelsen, Tina Vilsbøll, Jens J. Holst, Bolette Hartmann, Filip K. Knop, Morten Frost

Ստացեք ամբողջական տեքստը

Metabolic profile in patients with newly diagnosed bipolar disorder and their unaffected first-degree relatives ‌ Klara Coello, Maj Vinberg, Filip K. Knop, Bente K. Pedersen, Roger S. McIntyre, Lars V. Kessing, Klaus Munkholm

Ստացեք ամբողջական տեքստը

Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis. ‌ Heidi Storgaard, Lise L Gluud, Cathy Bennett, Magnus F Grøndahl, Mikkel B Christensen, Filip K Knop, Tina Vilsbøll

Ստացեք ամբողջական տեքստը

Supportive and non-supportive interactions in families with a type 2 diabetes patient: an integrative review ‌ Birgitte B. Bennich, Michael E. Røder, Dorthe Overgaard, Ingrid Egerod, Lene Munch, Filip K. Knop, Tina Vilsbøll, Hanne Konradsen

Ստացեք ամբողջական տեքստը

Separate and combined effects of long-term GIP and GLP-1 receptor activation in patients with type 2 diabetes: a structured summary of a study protocol for a double-blind, randomis... ‌ Tina Vilsbøll, Filip K Knop, Mads M Helsted, Lærke S Gasbjerg, Casper K Nielsen, Julie L Forman, Mikkel B Christensen

Ստացեք ամբողջական տեքստը

Semaglutide treatment for PRevention Of Toxicity in high-dosE Chemotherapy with autologous haematopoietic stem-cell Transplantation (PROTECT): study protocol for a randomised, doub... ‌ Filip K Knop, Hannelouise Kissow, Maria Ebbesen Sørum, Anne Ortved Gang, Dorte Maegaard Tholstrup, Sif Gudbrandsdottir, Brian Kornblit, Klaus Müller

Ստացեք ամբողջական տեքստը

evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomat... ‌ Jeffrey L. Cummings, Alireza Atri, Howard H. Feldman, Oskar Hansson, Mary Sano, Filip K. Knop, Peter Johannsen, Teresa León, Philip Scheltens

Ստացեք ամբողջական տեքստը